39th Annual Meeting and Scientific Sessions

Apr 2, 2019 ‐ Apr 6, 2019



Sessions

WEDNESDAY OPENING PLENARY SESSION

Apr 3, 2019 8:00am ‐ Apr 3, 2019 10:00am

Identification: PL01

Credits: None available.

Welcome/Program Chair Report
Lara Danziger-Isakov, MD, MPH

Thoracic Registry Report
Josef Stehlik, MD, MPH

IMACS Registry Report
Daniel Goldstein, MD

Journal Editor's Report
Mandeep Mehra, MD, FRCP, FACC, FESC

President's Report
Jeffrey Teuteberg, MD

Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Clinical Trial: Final Analysis of the 1028 Patient Full Cohort
Daniel Goldstein, MD,FACS,FACC

Expert Interactive Discussant for Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Clinical Trial: Final Analysis of the 1028 Patient Full Cohort
Robert Kormos, MD

INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) (Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil NCT03399604)
Nicholas Hill, MD

Expert Interactive Discussant for INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) (Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil NCT03399604)
Jean-Luc Vachiery, MD

Introductory Remarks to Lifetime Achievement Award Recipient
Keith McNeil, MD

Lifetime Achievement Award Recipient Lecture
John Wallwork, FRCS, FmedSci

Speaker(s):
  • Robert Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
  • Nicholas Hill, MD, Tufts Medical Center, Boston, MA, United States
  • Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium
  • Keith McNeil, MD, Papworth Hospital NHS Trust, Papworth Everard, United Kingdom
  • John Wallwork, FRCS, FmedSci, Papworth Hospital, Cambridge, United Kingdom
  • Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital, Cincinnati, OH, United States
  • Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, United States
  • Daniel Goldstein, MD,FACS,FACC, Montefiore Medical Center, Bronx, NY, United States
  • Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, United States
  • Jeffrey J. Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, United States
Tags: ALL
Free

SYMPOSIUM SESSION 05: Limiting the Invasiveness of the VAD Therapy: Alternative to Limited Surgical Approaches

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS05

Credits: None available.

Influence of the Surgical Technique on Post-Operative Outcome: Is Minimal Invasive Approach the Way to Go?
Victor Pretorius, MD

The Alternative Approach: Should We Be Using ECMO Instead of CPB?
Julia Riebandt, MD

Going 'Off-Pump': Does It Make a Difference?
Diyar Saeed, MD, PhD

Going 'BIVAD': Acute Pitfalls and Long-Term Threats
Evgenij Potapov, MD, PhD

Out with the Old: Pump Replacement/Upgrade Decommissioning Explant
Carmelo Milano, MD

Speaker(s):
Tags: MCS

RESEARCH SESSION 01: The Next Frontier for Thoracic Transplantation: Diagnostics and Therapies

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS01

Credits: None available.

(5) Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA
Kiran Khush, MD, MAS

(6) Distinct Heart Failure Phenotypes Identified by Myocardial Transcriptome Sequencing: Targets for Reverse Remodeling
Palak Shah, MD, MS

(315) Exosome Proteomics and Machine Learning Identify Novel Biomarkers of Primary Graft Dysfunction
Barry Fine, MD, PhD

(8) Engineered Mesenchymal Stromal Cell Therapy during Pig Ex Vivo Lung Perfusion and Transplant
Antti Nykanen, MD, PhD

(9) Hydrogen-Rich Preservation Solution Attenuates Lung Ischemia-Reperfusion Injury after Prolonged Cold Ischemia in a Canine Left Lung Transplant Model
Hidenao Kayawake, MD

(10) Atorvastatin Preserves Cardiac Contractility via Reducing Matrix Metalloproteinase-2 Isoforms Expression in a Diabetic Heart Model
Hye Won Lee, PhD

(11) Triptolide Attenuates Graft Inflammation During Ex Vivo Lung Perfusion
Sarah Burki, MD

Speaker(s):
  • Kiran Khush, MD, MAS, Stanford University, Stanford, CA, United States
  • Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, United States
  • Barry Fine, MD PhD, Columbia University, New York, NY, United States
  • Antti Nykanen, MD, PhD, University Health Network, Toronto, ON, Canada
  • Hidenao Kayawake, MD, Kyoto University, Kyoto, Japan
  • Hye Won Lee, PhD, Pusan National University Hospital, Busan, Korea, Republic of
  • Sarah Burki, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Tags: PEDS LTX BSTR PATH

SYMPOSIUM SESSION 02: Future Shock: Great Debates in Cardiogenic Shock

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS02

Credits: None available.

CASE PRESENTATION: 'Gimme Gimme Shock Treatment': Acute cardiogenic shock patient transferred for advanced heart failure therapy
Adriana Torres, MD

DEBATE 1: ‘Culture Shock’: Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (PRO)
Daniel Goldstein, MD

DEBATE 1: ‘Culture Shock’: Tissue Perfusion is More Important than Hemodynamics in Managing Cardiogenic Shock (CON)
James Fang, MD

DEBATE 2: ‘Shock Rock’: One Treatment Fits All in Cardiogenic Shock (PRO)
Shelley Hall, MD

DEBATE 2: ‘Shock Rock’: One Treatment Fits All in Cardiogenic Shock (CON)
Rebecca Cogswell, MD

DEBATE 3: ‘Shock Treatment’: All Patients Should Receive Temporary MCS in Cardiogenic Shock to Maximize Survival (PRO)
Pascal Leprince, MD

DEBATE 3: ‘Shock Treatment’: All Patients Should Receive Temporary MCS in Cardiogenic Shock to Maximize Survival (CON)
David Baran, MD

Speaker(s):
  • Adriana Torres, MD, LosCobos Medical Center, Bogota, Colombia
  • Daniel Goldstein, MD,FACS,FACC, Montefiore Medical Center, Bronx, NY, United States
  • James Fang, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States
  • Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, United States
  • Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, United States
  • Pascal Leprince, MD, Hôpital de La Petie Salpetriere, Paris, France
  • David Baran, MD, Sentara Heart Hospital, Norfolk, VA, United States
Tags: MCS HF-HTX

RESEARCH SESSION 03: Chronic Lung Allograft Dysfunction: Anything New?

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS03

Credits: None available.

(12) Diffusing Capacity for Carbon Monoxide (DLCO): A Predictor of CLAD and Death after Lung Transplantation in a 20-Year Longitudinal Study
David Darley, BSc, MBBS (Hons), FRACP

(13) Molecular Analysis of Transbronchial and Mucosal Biopsies in Patients with CLAD
Michael Parkes, MSc.

(14) Predictive Biomarkers for Bronchiolitis Obliterans
Vaidehi Kaza, MD

(15) Chest CT Has Prognostic Value at BOS Diagnosis after Lung Transplantation
Anke Van Herck, MD

(16) Regulatory T Cells in Asymptomatic ISHLT Grade A1 Rejection and the Risk of Chronic Lung Allograft Dysfunction
Matthew White, Master's

(17) Emergence of a Specific Intrapulmonary CD4+ T Cell Subset Prior to the Onset of Lung Allograft Dysfunction
Sajad Moshkelgosha, PhD

(18) Increased Hazard of Chronic Lung Allograft Dysfunction in the Presence of Persistent and Complement Fixing Donor-Specific Antibodies
Carlo Iasella, PharmD

Speaker(s):
  • David Darley, BSc MBBS (Hons) FRACP, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
  • Michael Parkes, MSc., University of Alberta, Edmonton, AB, Canada
  • Vaidehi Kaza, MD, UT Southwestern Medical Center, Dallas, TX, United States
  • Anke Van Herck, MD, University Hospitals Leuven, Leuven, Belgium
  • Matthew White, Master's, Toronto General Research Institute, Toronto, ON, Canada
  • Sajad Moshkelgosha, PhD, University Health Network, Toronto, ON, Canada
  • Carlo Iasella, PharmD, University of Pittsburgh, Pittsburgh, PA, United States
Tags: LTX BSTR PATH

RESEARCH SESSION 04: So Wrong It's Right: The Right Ventricle and MCS

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS04

Credits: None available.

(19) Right Ventricular Strain as a Predictor of Post-LVAD Early Right Ventricular Failure
Lusha Liang, MD

(20) Serial Assessment of Pulmonary Artery Pulsatility Index Provides Incremental Risk Assessment for Early Right Ventricular Failure after Left Ventricular Assist Device Implantation
Matthew Gonzalez, MD

(21) Bridging Biventricular Failure to Successful Heart Transplants: HVAD BiVAD versus TAH
Eugene DePasquale, MD

(22) New Insights into Right Ventricular Function among Patients with Left Ventricular Assist Devices Using High Fidelity Conductance Catheters to Generate Real Time Pressure Volume Loops
William Cornwell, MD

(23) Early and Late Right Heart Failure Following LVAD Implantation: Epidemiology, Natural History and Outcomes. An Analysis of the STS INTERMACS Database
Chris Kapelios, MD

(24) Pectoralis Muscle Attenuation Improves the Prediction of Right Ventricular Failure after LVAD Implantation
Hirak Shah, MD

(25) Oral Milrinone for the Treatment of Right Ventricular Failure in LVAD Patients
Nir Uriel, MD, MSc

Speaker(s):
  • Lusha Liang, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
  • Matthew Gonzalez, MD, Cleveland Clinic Foundation, Cleveland, OH, United States
  • Eugene C. DePasquale, MD, UCLA, Los Angeles, CA, United States
  • William Cornwell, MD, University of Colorado, Denver, CO, United States
  • Chris Kapelios, MD, National and Kapodestrian University of Athens, Athens, Greece
  • Hirak Shah, MD, University of Minnesota, Minneapolis, MN, United States
  • Nir Uriel, MD, MSc, University of Chicago, Chicago, IL, United States
Tags: MCS PH PHARM

RESEARCH SESSION 06: Pediatric Donor Utilization, MCS, Readmissions and More

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS06

Credits: None available.

(26) Donor Utilization in the Australian National Paediatric Heart Transplant Program: Stretching the Limits
Julie Wacker, MD

(27) Regional Variation in Donor Refusal Rates Correlates with Poor Wait List Outcomes
Ryan Davies, MD

(417) Toward a New Strategy for Pediatric Heart Allocation: High Risk Organs for Less Ill Patients?
Adam Morrison, MD

(29) Anti-Coagulation Management in Pediatric Ventricular Assist Device: A Quality Improvement Target
Christina VanderPluym, MD

(30) Role of ECMO as Bridge to VAD Therapy in Critically Ill Pediatric Patients - An Analysis of the STS Pedimacs Database
Syed Peer, MD

(31) Hospital Readmission Following Pediatric Heart Transplantation
William Mahle, MD

(32) Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus
Adam Putschoegl, DO

Speaker(s):
  • Julie Wacker, MD, The Royal Children's Hospital Melbourne, Parkville, Australia
  • Ryan R Davies, MD, UT Southwestern - Children's Health Dallas, Dallas, TX, United States
  • Adam Morrison, MD, Nationwide Children's Hospital, Columbus, OH, United States
  • Christina VanderPluym, MD, Boston Children's Hospital, Boston, MA, United States
  • Syed Peer, MD, Children’s National Health System Washington, DC, United States
  • William Mahle, MD, Children's Healthcare of Atlanta, Atlanta, GA, United States
  • Adam Putschoegl, DO, Children's Hospital Colorado, Aurora, CO, United States
Tags: MCS PEDS HTX HF

SYMPOSIUM SESSION 07: Making Co-Morbidities Great Again: Practical Updates in Co-Morbidity Management

Apr 3, 2019 10:30am ‐ Apr 3, 2019 12:15pm

Identification: SS07

Credits: None available.

What to Do When the A1C is ‘BIGLY’: An Update on the Management of Post-Transplant Diabetes
Jennifer Day, PharmD

Good Lipoproteins on Both Sides: Optimizing Treatment of Dyslipidemia and Obesity
Jill Krisl, PharmD

'Skeletons in the Closet': Diagnosis, Prevention and Treatment of Osteoporosis
David Iturbe, MD

'Stable Genius': Managing Mental Health After Transplant
Melissa Sanchez, BSc Hons

Combating 'Alternative Facts': Complementary and Alternative Medicine in Transplant
Teena Sam, PharmD

'Fake News': Immunization Practices and Travel Prophylaxis
Michele Estabrook, MD

Speaker(s):
  • Jennifer Day, PharmD, Baptist Health Heart Failure and Transplant Institute, Little Rock, AR, United States
  • Jill Krisl, PharmD, Houston Methodist Hospital, Houston, TX, United States
  • David Iturbe, MD, Hospital Universitario Marques de Valdecilla, Santander, Spain Spain
  • Melissa Sanchez, BScHons, PGDip, MSc, DClinPsy, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom
  • Teena Sam, PharmD, Baylor University Medical Center, Dallas, TX, United States
  • Michele Estabrook, MD, St. Louis Children's Hospital, St Louis, MO, United States

RESEARCH SESSION 08: ISHLT Spotlight: Heart Transplantation in Latin America

Apr 3, 2019 12:45pm ‐ Apr 3, 2019 1:45pm

Identification: SS08

Credits: None available.

(33) Sequential Measurement of Trypanosoma cruzi Parasitic Load in Endomyocardial Biopsies for Early Detection and Follow-up of Chagas Disease Reactivation After Heart Transplantation
Luiz Benvenuti MD, PhD

(34) The Paradigm of Gender: Mismatch and Its Influence on Short and Long-Term Outcomes after Heart Transplantation
Mónica Gilbert, MD

(35) Incidence of Right Ventricular Dysfunction in Adult Patients Submitted to Heart Transplantation According to the Presence of Pre-Transplant Pulmonary Hypertension
Fabiana Marcondes-Braga MD, PhD

(36) The Effect of Donor-Recipient Heart Mass and Size Matching in Primary Graft Dysfunction Development after Heart Transplantation
Mónica Gilbert, MD

(37) Endomyocardial Biopsy after Heart Transplantation. When is Too Late?
Luis Guerrero Cepeda, MD

Speaker(s):
Tags: ID PATH EEP HF-HTX

SYMPOSIUM SESSION 09: Re-Focusing the Blurry Vision: Biomarkers of Thoracic Allograft Rejection

Apr 3, 2019 2:00pm ‐ Apr 3, 2019 3:45pm

Identification: SS09

Credits: None available.

Date of CE Release October 15, 2019

Date of CE Expiration October 14, 2022

Location Online

Acknowledgement of Financial and/or In-Kind Commercial Support - No financial or in-kind commercial support was received for this educational activity.

Session Description The goal of this session is to review advances in molecular diagnostic assessments and novel biomarkers in thoracic (both heart and lung) organ transplantation.

Target Audience
Physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.

Session Objective At the conclusion of this course participants will have improved competence and professional performances in the areas of emerging technologies, medical advances, and the clinical applications of basic modes of advanced heart and lung disease management. This will include approaches that are being applied clinically and others that are investigational but that can provide greater insight into the pathophysiology and immunology of allograft rejection.

Satisfactory Completion Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.

Physicians

Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

Credit Designation Statement - ISHLT designates this enduring material activity for a maximum of 1.50 AMA PRA Category 1 credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Pharmacists

custom image

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 1.50 contact hours for nurses and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of completing the online activity to meet the deadline for submission to CPE Monitor.

Learner Attributes: Medical Knowledge

Disclosures Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or services as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Disclosures for this Activity

Moderators

Daniel Kreisel, MD, PhD – Biomedical Systems (Wife):Consultant,Seattle Genetics (Wife):Speakers Bureau,Compass:Scientific/Medical Advisory Board Meber,Compass:Research Grant Overall Principal Investigator.

Tereza Martinu, MD, PhD – Therabron Inc.:Consultant,Cystic Fibrosis Foundation (not-for-profit):Consultant.

Speakers

Hannah Valantine, MD – No relevant financial rel;ationships to disclose.

Glen Westall, MD, PhD – Ziagen:Research Grant Site Principal Investigator,CSL:Research Grant Overall Principal Investigator,One Lamda:Research Grant Site Principal Investigator.

P. Christian Schulze, MD, PhD – No relevant financial relationships to disclose.

Martin Goddard, FRCS, MRCPa – No relevant financial relationships to disclose

Jean-Paul Duongm Van Huyen, MD – Lung Bioneerging; Site PI, Consultant

Staff

Jenny Clark - No relevant financial relationships to disclose
Amanda Rowe – No relevant financial relationships to disclose
Sheryl Morgan – No relevant financial relationships to disclose

Disclaimer The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of ISHLT.

Contact Information If you have questions regarding this enduring material activity, please contact Jenny Clark at Jenny.Clark@ishlt.org.


Donor-Derived Cell Free DNA as a Marker of Allograft Injury
Hannah Valantine, MD

Monitoring Immune Responses
Glen Westall, MD, PhD

MicroRNA and Exosomes
P. Christian Schulze MD, PhD

Through the Looking Glass: Advances in Histology
Martin Goddard, FRCS, MRCPa

Gene Expression Signatures to Monitor Graft Rejection
Jean-Paul Duong Van Huyen, MD

Speaker(s):
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content